Short-term intensive insulin therapy in type 2 diabetes mellitus: A systematic review and meta-analysis

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 1, 2013, Pages 28-34

  Kramer, Caroline Kaercher ^a,b   Zinman, Bernard ^a,b   Retnakaran, Ravi ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BODY MASS; CONTINUOUS INFUSION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; RESPONSIBILITY; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PROSPECTIVE STUDIES;

EID: 84882644764     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70006-8     Document Type: Article

References (26)

1. Kahn SE, Zraika S, Utzschneider KM, Hull RL The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 2009, 52:1003-1012.
2. Nolan CJ, Damm P, Prentki M Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011, 378:169-181.
3. Wajchenberg BL Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28:187-218.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
5. Retnakaran R, Drucker DJ Intensive insulin therapy in newly diagnosed type 2 diabetes. Lancet 2008, 371:1725-1726.
6. Retnakaran R, Zinman B Short-term intensified insulin treatment in type 2 diabetes: long-term effects on beta-cell function. Diabetes Obes Metab 2012, 14(suppl 3):161-166.
7. Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008, 31:1927-1932.
8. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
9. Moher D, Liberati A, Tetzlaff J, Altman DG Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W64.
10. Higgins JP, Thompson SG Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
11. Begg CB, Mazumdar M Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
12. Duval S, Tweedie R Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000, 56:455-463.
13. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27:2597-2602.
14. Chen H, Ren A, Hu S, Mo W, Xin X, Jia W The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007, 75:327-332.
15. Zhao QB, Wang HF, Sun CF, Ma AQ, Cui CC Effect of short-term intensive treatment with insulin pump on beta cell function and the mechanism of oxidative stress in newly diagnosed type 2 diabetic patients. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27:1878-1879. (in Chinese).
16. Chen A, Huang Z, Wan X, et al. Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012, 35:474-481.
17. Liu L, Wan X, Liu J, Huang Z, Cao X, Li Y Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol Ther 2012, 14:756-761.
18. Li HQ, Wang BP, Deng XL, et al. Insulin improves beta-cell function in glucose-intolerant rat models induced by feeding a high-fat diet. Metabolism 2011, 60:1566-1574.
19. Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz PU Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res 1985, 4:110-125.
20. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52:102-110.
21. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008, 10(suppl 4):32-42.
22. Opsteen C, Qi Y, Zinman B, Retnakaran R Effect of short-term intensive insulin therapy on quality of life in type 2 diabetes. J Eval Clin Pract 2012, 18:256-261.
23. Retnakaran R, Yakubovich N, Qi Y, Opsteen C, Zinman B The response to short-term intensive insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010, 12:65-71.
24. Ryan EA, Imes S, Wallace C Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
25. Hsu WC, Boyko EJ, Fujimoto WY, et al. Pathophysiologic differences among Asians, native Hawaiians, and other Pacific Islanders and treatment implications. Diabetes Care 2012, 35:1189-1198.
26. Retnakaran R, Qi Y, Opsteen C, Vivero E, Zinman B Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral anti-diabetic medications: a pilot study with sitagliptin. Diabetes Obes Metab 2010, 12:909-915.